AngioDynamics (ANGO) Q3 Earnings and Revenues Miss Estimates

AngioDynamics, Inc. (ANGO) reported an adjusted loss per share of 16 cents for third-quarter fiscal 2024, wider than the year-ago loss of 3 cents per share and the Zacks Consensus Estimate of a loss of 14 cents per share.On a pro-forma basis (excluding Dialysis and BioSentry businesses, the divested PICC and Midline product portfolios and the discontinued Uniblate, Starburst and Syntrax products), adjusted loss per share in third-quarter fiscal 2024 was also 16 cents, wider than the adjusted loss per share ...